

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. [Lilly to Cut 3,500 Jobs and Close Three Facilities](#)

Eli Lilly and Company plans to reduce its global workforce by 3,500 positions and close an animal-health manufacturing facility and two R&D facilities in New Jersey and China. Lilly expects the majority of the positions eliminated to come from a US voluntary early-retirement program. [Read More](#)

2. [Novartis' CEO To Retire; New CEO Appointed](#)

Joseph Jimenez, CEO of Novartis plans to retire in 2018 and to step down as CEO after eight years in the position. The company has appointed Vasant Narasimhan, MD, now global head of drug development and chief medical officer, as the new CEO, effective February 1, 2018. [Read More](#)

3. [Merck & Co. To Acquire Rigontec in a Deal Worth up to \\$554 Million](#)

Merck & Co. has agreed to acquire Rigontec, a Bonn, Germany-headquartered biopharmaceutical company focused on cancer immunotherapies, in a deal worth up to EUR 464 million (\$554 million). Rigontec's lead product is a Phase I candidate for treating various tumors. [Read More](#)

4. [Merck KGaA Considers Strategic Options for OTC Business](#)

Merck KGaA reports that it is preparing strategic options for its Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships. [Read More](#)

5. [Merck KGaA Completes Divestment of Biosimilars Business](#)

Merck KGaA has completed its divestment of its biosimilars business to Fresenius after receiving the necessary regulatory approvals. The companies had announced the deal in April. [Read More](#)

6. [AMRI Completes Acquisition by Investment Firms](#)

Albany Molecular Research Inc. (AMRI), a contract research, development, and manufacturing organization, has completed its acquisition by affiliates of The Carlyle Group and affiliates of GTCR LLC, two investment firms. AMRI had announced the acquisition in June. [Read More](#)

7. [Mylan's, Biocon's Herceptin Biosimilar Delayed by FDA](#)

The FDA has extended its target action date by three months for the biologics license application for a biosimilar of trastuzumab from Mylan and Biocon, a Bangalore, India-based pharmaceutical company. Herceptin is a top-selling drug for Roche with 2016 sales of CHF 6.78 billion (\$7.04 billion). This is part of *DCAT Value Chain Insights* Pipeline News. [Read More](#)

8. [FDA OKs Pfizer's ADC Mylotarg](#)

The FDA has approved Pfizer's Mylotarg (gemtuzumab ozogamicin), an antibody drug conjugate (ADC) for treating certain forms of leukemia, marking Pfizer's second recent ADC approval. This is a part of *DCAT Value Chain Insights* Drug Approval News. [Read More](#)

9. [Lilly to Resubmit NDA to FDA for Arthritis Drug](#)

Eli Lilly and Company and Incyte Corporation, a biopharmaceutical company, plan to resubmit a new

drug application (NDA) for their rheumatoid arthritis drug, baricitinib, to the FDA before the end of January 2018. Prior to certain delays, the drug had been projected for blockbuster status by some analysts. This is part of *DCAT Value Chain Insights* Pipeline News. [Read More](#)

10. [FDA Plans to Strengthen Inspections and Manufacturing Oversight](#)

FDA Commissioner Scott Gottlieb outlined the steps that the agency is taking to more fully integrate the agency's drug-review programs with its facility evaluations and inspections for human drugs through the Center for Drug Evaluation and Research and the Office of Regulatory Affairs. [Read More](#)

The DCAT organization is happy to provide this service to its members each Friday. Have a great weekend!

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org